July 30, 2021 - ROSEN LOGO.jpg
ROSEN, THE FIRST FILING FIRM, Encourages Paycom Software, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Initiated by the Firm – PAYC
19 nov. 2023 13h20 HE | The Rosen Law Firm PA
NEW YORK, Nov. 19, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of...
July 30, 2021 - ROSEN LOGO.jpg
NATIONALLY RANKED ROSEN LAW FIRM Encourages Paycom Software, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm – PAYC
16 nov. 2023 13h55 HE | The Rosen Law Firm PA
NEW YORK, Nov. 16, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of...
ZENITH-LOGO-RGB.jpg
Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic Castration-Resistant Prostate Cancer (mCRPC) Study
21 sept. 2021 08h00 HE | Zenith Capital Corp.
CALGARY, Alberta, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) and Newsoara BioPharma Co., Ltd. (“Newsoara”) announced today the initiation of a...
ZENITH-LOGO-RGB.jpg
Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer
27 juin 2019 08h30 HE | Zenith Capital Corp.
CALGARY, Alberta, June 27, 2019 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”), a wholly-owned subsidiary of Zenith Capital Corp., announced today that it has dosed the...
ZENITH-LOGO-RGB.jpg
Zenith Epigenetics Announces U.S. FDA Clearance of Investigational New Drug Application for ZEN-3694 in TNBC Program
18 mars 2019 09h00 HE | Zenith Capital Corp.
Pfizer / Zenith TNBC program collaboration on target to dose first patient in April 2019 Phase 2 mCRPC program and clinical data to be presented at AACR CALGARY, Alberta, March 18, 2019 (GLOBE...
ZENITH-LOGO-RGB.jpg
Zenith Epigenetics Announces Clinical Trial Collaboration with Pfizer
20 nov. 2018 08h30 HE | Zenith Capital Corp.
Collaboration to evaluate ZEN-3694 in combination with Talazoparib in TNBC patients; Phase 1b/2 trial expected to initiate 1Q 2019 CALGARY, Alberta, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Zenith...